Theramex gains €10M in licensing deal

Merck affiliate Laboratoire Theramex will pocket a €10 million licensing payment from Organon for the marketing rights to its new contraceptive EMM 310066, which has demonstrated efficacy in a Phase II trial. Theramex retains marketing rights in certain companies and also stands to garner milestones and royalties.

- read this story from AFX for more on the deal

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.